What were the key takeaways from Quest Diagnostics’s earnings call?

What is the market's earnings forecast for Quest Diagnostics next quarter?

What is Quest Diagnostics's gross profit margin?

What is Quest Diagnostics's latest dividend and current dividend yield?

What guidance did Quest Diagnostics's management provide for the next earnings period?

What were the key takeaways from Quest Diagnostics's earnings call?

What factors drove the changes in Quest Diagnostics's revenue and profit?

What does Quest Diagnostics do and what are its main business segments?

- **Topline Growth**: Q4 2025 revenue up 7.1% YoY, full-year 2025 EPS up 11%, driven by >20% consumer testing growth and Co-Lab scale-up.
- **Strategic Wins**: $1B+ Corewell Health deal, 85-biomarker Elite Health profile launch, and >20% growth in advanced diagnostics (AD-Detect, MRD tests).
- **Margin Outlook**: 2026 operating margin expansion despite $0.25 EPS dilution from Project Nova, with consumer business and LifeLabs offsetting Co-Lab ramp costs.
- **PAMA Relief**: 2026 free of rate cuts, but 2027 data collection shift to 2025. Company pushing for RESULTS Act to fix flawed PAMA methodology.
- **Pipeline Momentum**: Flow MRD launch, Haystack MRD less dilutive, and GRAIL/Guardant partnerships adding $10M+ in 2026 revenue.

**【CEO Summary Section】**
- Quest Diagnostics reported 7.1% year-over-year revenue growth in Q4 2025, driven by organic growth across physician, hospital, and consumer channels. Full-year 2025 revenue grew 15%, with EPS up 11%.
- CEO Jim Davis highlighted strategic wins: scaling Co-Lab solutions with Corewell Health (projecting $1B+ annual revenue by 2026), expanding dialysis testing with Fresenius Medical Care, and launching advanced diagnostics like the 85-biomarker Elite Health profile on questhealth.com.
- Consumer-initiated testing grew >20% in 2025, exceeding prior guidance, with partnerships with WHOOP, Oura, and others driving growth.
- PAMA rate cuts delayed until 2027, but company continues advocating for structural reforms via the RESULTS Act.

**【CFO Financial Commentary】**
- Q4 2025: 
  - Revenues: $2.81B (7.1% YoY), with 6.4% organic growth
  - Adjusted EPS: $2.42 (10% YoY)
  - Operating margin: 15.3% (down 30bps vs. prior year due to Co-Lab ramp costs)
- 2026 Guidance: 
  - Revenues: $11.7B-$11.82B (6%-7.1% growth)
  - Adjusted EPS: $10.50-$10.70
  - Operating margin expansion despite $0.25 EPS dilution from Project Nova
- Free cash flow expected at $1.75B, down from 2025 due to one-time tax benefits and an extra payroll cycle.

**【Q&A Key Highlights】**
- **Consumer Growth**: Questhealth.com grew 35% in 2025, with >20% CAGR expected. Wearable partnerships (e.g., Oura, WHOOP) drive recurring revenue with 70%+ renewal rates.
- **Margin Dynamics**: Corewell Health adds $250M in 2026 revenue at low single-digit margins, but LifeLabs (Canada) and consumer business offset with high-margin growth.
- **PAMA Impact**: 2026 free of PAMA cuts, but 2027 rate setting will use 2025 data (vs. 2019). Company optimistic about RESULTS Act passage.
- **Oncology Pipeline**: Flow MRD test launched in January, Haystack MRD less dilutive in 2026. GRAIL and Guardant partnerships add $10M+ in 2026 revenue.
- **Operational Resilience**: Q1 2026 weather impact (~$10M) expected to recover, with strong January trends resuming post-storms.

Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 13.1% YoY to $2.82B, driven by 6.8% organic growth in advanced diagnostics and consumer channels.
- **Strategic Wins**: $1B+ annual Co-Lab deal with Corewell Health; AD-Detect volumes double QoQ.
- **Consumer Momentum**: questhealth.com up 30-40% YoY; WHOOP/OURA partnerships to launch Q4.
- **Margin Risks**: $100M PAMA impact in 2026 if no relief; elevated medical costs (+40-50bps Q3 margin drag).
- **Innovation Lead**: FDA Breakthrough for Haystack MRD; 25+ clinical studies underway for MRD testing.

**【CEO Opening Remarks】**
- Q3 2025 revenue grew 13.1% YoY to $2.82 billion, with 6.8% organic growth driven by advanced diagnostics, acquisitions, and consumer channel expansion.
- Announced a joint venture with Corewell Health in Michigan, expected to generate $1 billion annually from Co-Lab solutions.
- Highlighted strong demand for AI-driven innovations like AD-Detect (Alzheimer's test) and Haystack MRD (cancer monitoring), with AD-Detect volumes doubling QoQ.
- Consumer health partnerships with WHOOP and OURA are driving direct-to-consumer growth, with questhealth.com up 30-40% YoY.
- Raised full-year 2025 guidance: revenue $10.96-11.0 billion, adjusted EPS $9.76-9.84.

**【CFO Financial Commentary】**
- GAAP EPS: $2.16 (vs. $1.99 YoY), Adjusted EPS: $2.60 (vs. $2.30 YoY), driven by 16.3% operating margin (vs. 15.5% YoY).
- Cash flow from operations: $1.42 billion YTD (63% YoY growth), guided to $1.8 billion for 2025.
- Project Nova investments (~$30 million in 2025) will modernize order-to-cash processes but may impact near-term margins.
- Warned of $100 million PAMA-related margin pressure in 2026 if no legislative relief.

**【Q&A Highlights】**
- **Utilization Trends**: Organic req volume +3.9% YoY, driven by autoimmune, cardiometabolic, and consumer testing. Test mix improvement (+3% rev/req) expected to continue.
- **PAMA Risk**: 50% chance of delay vs. 50% chance of Results Act passage; $100M margin impact if no relief, partially offset by cost control.
- **Consumer Channel**: Direct-to-consumer growth (~30-40% YoY) and partnerships with WHOOP/OURA expected to accelerate in Q4.
- **Project Nova**: $310M 6-year investment to digitize workflows; 2026 spend will be paced based on PAMA outcome.
- **Haystack MRD**: FDA Breakthrough Designation; ~$100M+ revenue potential in 2026 as reimbursement expands.


Quest Diagnostics Incorporated (DGX) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: 15.2% YoY growth driven by 5.2% organic expansion and acquisitions; adjusted EPS up 11.5%.
- **Strategic Wins**: Advanced diagnostics (AD-Detect, Haystack MRD) and functional medicine partnerships fueling double-digit growth.
- **Operational Efficiency**: 3% annual cost savings target on track; automation investments improving lab productivity.
- **Guidance Raise**: Full-year 2025 revenue raised to $10.8-$10.92B, reflecting 3.5-4% organic growth and Project Nova investments.
- **Risk Mitigation**: PAMA cuts ($100M potential impact) and tariffs manageable; wage inflation stable at 3-4%.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $2.76 billion, up 15.2% YoY, driven by 5.2% organic growth and acquisitions. Adjusted EPS rose 11.5% to $2.62.
- **Strategic Initiatives**: Advanced diagnostics (e.g., AD-Detect, Haystack MRD) and functional medicine partnerships are key growth drivers. Automation and AI investments (e.g., front-end lab automation) are improving efficiency.
- **Market Expansion**: New relationships with Fresenius Medical Care and expanded access via Elevance and Sentara are boosting enterprise and consumer channels.
- **Guidance Update**: Full-year 2025 revenue raised to $10.8-$10.92 billion, with adjusted EPS of $9.63-$9.83, reflecting 3.5-4% organic growth and Project Nova investments.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP EPS of $2.47 vs. $2.03 YoY; cash from operations up 67.1% to $858M. Operating margin expanded to 16.9% of revenue.
- **Cost Management**: 3% annual cost savings target via automation; wage inflation stable at 3-4%.
- **Risk Mitigation**: Absorbing $100M potential PAMA impact through pricing actions; tariffs in China/Europe manageable within guidance.

**【Q&A Key Highlights】**
- **Regulatory Impact**: One Big Beautiful Bill expected to reduce exchange volumes by 30-40 bps in 2026; Medicaid impact negligible. PAMA cuts could reduce 2026 revenue by $100M, partially offset by pricing adjustments.
- **Tariff Management**: 80% of $2B supply chain in U.S.; contracts mitigate China/Europe tariff risks.
- **Acquisition Performance**: LifeLabs contributed 8% of M&A revenue growth; integration driving procurement and operational synergies.
- **Functional Medicine Growth**: Consumer-initiated testing (e.g., women's hormone panels) up 40%; functional medicine partnerships growing double digits.
- **Haystack MRD Progress**: Early adoption from oncologists; study validates test's sensitivity and specificity for immunotherapy response monitoring.

Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript

- **Revenue Beat Expectations**: 12.1% YoY growth to $2.65B, driven by 2.5% organic growth despite weather impacts.
- **Strategic Wins**: Optum preferred lab network expansion, Fresenius dialysis testing partnership, and AD-Detect test adoption highlight advanced diagnostics leadership.
- **Profitability Strength**: 15.3% adjusted operating margin, 8.3% EPS growth to $2.21, with $1.5B 2025 cash flow guidance.
- **Tariff Mitigation**: <1% China-sourced reagents, 80%+ U.S.-manufactured critical supplies, and multi-year contracts limit risk.
- **Haystack Progress**: Commercial orders received, with GenAI EMR integration planned for oncologists.
- **Resilience to Economic Downturns**: 8% Medicaid exposure, stable patient testing demand, and 3% organic growth guidance reflect operational discipline.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue increased 12.1% YoY to $2.65 billion, driven by 2.5% organic growth despite weather-related disruptions. Key drivers included acquisitions, large enterprise partnerships (e.g., Optum, Fresenius), advanced diagnostics expansion, and new health plan access.
- **Strategic Investments**: Continued focus on automation, robotics, and AI to improve quality, customer experience, and productivity. Project Nova aims to modernize order-to-cash processes, supported by a Google Cloud collaboration for GenAI personalization.
- **FDA LDT Litigation Impact**: Court ruling vacating FDA LDT rule preserves access to innovative testing services. Quest maintains regulatory compliance in global and life sciences businesses, with $10M+ annual investments in quality systems.
- **Advanced Diagnostics Momentum**: Double-digit growth in cardiometabolic, autoimmune, brain health (AD-Detect test adoption), and oncology (Haystack MRD test orders). Consumer-initiated testing platform (Questhelp.com) saw 10 new test launches and increased first-time orders.
- **Operational Efficiency**: Targeting 3% annual cost savings through Invigorate program. Q1 2025 operating margin expanded 50bps to 15.3%, with adjusted EPS up 8.3% YoY to $2.21.

**【CFO Financial Highlights】**
- **Revenue Breakdown**: Diagnostic Information Services grew 12.7% YoY, driven by physician and hospital channel expansion. Organic revenue per requisition increased 3.6% YoY, offsetting lower LifeLabs contribution.
- **Profitability**: Adjusted operating income rose 16.3% YoY to $406 million (15.3% of revenue). Cash flow improved to $314 million Q1 vs. $154 million prior year, supported by $50M payroll tax credit gain.
- **Guidance**: Full-year 2025 revenue ($10.7-10.85B) and adjusted EPS ($9.55-9.80) unchanged, reflecting 3% organic growth assumption. Capital expenditures expected at $500 million, with $1.5B cash flow from operations.

**【Q&A Key Themes】**
- **Tariff Exposure Management**: <1% of $2B reagent/supply spend sourced directly from China. 80%+ of critical reagents manufactured in the U.S. under multi-year contracts. Any tariff impact manageable within guidance.
- **LifeLabs Integration Progress**: Margins improving quarter-over-quarter, on track to meet corporate average within 2-3 years. British Columbia strike limited to 17 of 128 centers, expected resolution within 45 days.
- **Haystack MRD Test Adoption**: Received commercial orders, with Medicare and private payer reimbursement submissions underway. GenAI integration with Epic EMR for oncologists planned Q4 2025.
- **Policy Risks**: 8% of revenue tied to Medicaid; ACA exchange expansion provides stability. PAMA reform advocacy continues, with potential delay of 2027 cuts if no reform progress.
- **Economic Resilience**: Patient testing demand stable during past recessions. 2025 guidance assumes 3% organic growth, with $10M+ annual investments in regulatory compliance and Project Nova modernization.

Quest Diagnostics (DGX)-22 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: Q4 14.5% revenue growth ($2.62B), 3%+ organic growth in 2025 driven by 8 acquisitions (LifeLabs, 4 U.S. outreach labs).
- **Advanced Diagnostics Expansion**: 15%+ growth in brain health, cardiometabolic, and oncology; Haystack MRD test launched commercially in 2025.
- **Operational Efficiency**: 3% cost savings from automation/AI; 2025 margin expansion to 15.6%+ adj. operating margin.
- **Key Risks**: $0.20/year IT/LDT investments, 2025 weather risks (Q1 wildfires/snowstorms), and FDA regulatory uncertainty.
- **Strategic Focus**: Accelerating growth through advanced diagnostics, health plan partnerships (90%+ U.S. in-network), and IT modernization.

**【CEO Summary Section】**
- Delivered 14.5% Q4 revenue growth ($2.62B), including 4.8% organic growth and 5% full-year organic growth.
- Completed 8 acquisitions in 2024, including LifeLabs in Canada, driving 3%+ organic revenue growth and 7%+ total revenue growth.
- Advanced diagnostics growth: 15%+ in brain health, cardiometabolic, and oncology; Haystack MRD test launched commercially in 2025.
- Operational efficiency: 3% cost savings from automation/AI (e.g., Clifton lab automation), improving retention and productivity.
- 2025 guidance: $10.7-10.85B revenue, $9.55-9.80 adj. EPS, 3%+ organic growth, and margin expansion.

**【CFO Financial Commentary】**
- Q4 adj. EPS: $2.23 (vs. $2.15 prior year), driven by organic growth and acquisitions, offset by $0.06 weather impact.
- 2025 financials: $1.45B cash from ops, $500M capex, 25% tax rate, and 114M diluted shares.
- Key headwinds: $0.20 IT/LDT compliance investments, wage inflation, and weather (30bps margin impact in Q4).
- Margin expansion: 15.6% Q4 adj. operating margin, targeting higher in 2025 despite LifeLabs' lower-margin contribution.

**【Q&A Highlights】**
- **Utilization trends**: Core physician/hospital req volume strong, test-per-request up 3.3% organically; Medicare Advantage growth driving mix.
- **Rev/req dynamics**: 2/3 growth from test mix (e.g., AD-Detect, ApoB), 1/3 from payer mix; 2025 test-per-request growth to moderate.
- **FDA/LDT investments**: $0.20/year for IT modernization and FDA compliance; potential 2026+ savings if regulatory environment stabilizes.
- **Acquisition strategy**: 2025 pace to moderate, focusing on 2024 acquisitions' productivity; tuck-in M&A for outreach labs expected.
- **Haystack MRD**: 2025 revenue contribution from 70+ academic/community oncology partnerships; Medicare payment progress ongoing.
- **PAMA update**: Bipartisan support for reform; 2025 focus on resolving rate cuts and ensuring fair reimbursement.

Actual																0.94	1.42	4.31	4.48	3.76	3.18	3.96	3.33	3.22	2.36	2.36	1.98	2.04	2.3	2.22	2.15	2.04	2.35	2.3	2.23	2.21	2.62	2.6	2.42
Forecast																0.8811	0.7121	3.7175	4.1705	3.7117	2.8709	2.8755	3.222	2.9921	2.2914	2.1935	1.911	1.9746	2.2668	2.1883	2.1136	1.8556	2.3348	2.2637	2.1859	2.1516	2.5705	2.503	2.3703	2.3694
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+6.68%	+99.41%	+15.94%	+7.42%	+1.30%	+10.77%	+37.72%	+3.35%	+7.62%	+2.99%	+7.59%	+3.61%	+3.31%	+1.46%	+1.45%	+1.72%	+9.94%	+0.65%	+1.60%	+2.02%	+2.71%	+1.93%	+3.88%	+2.10%	0.00%

DGX

DGX fundamentals

DGX Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

DGX

DGX fundamentals

DGX Q1 2026 Earnings Preview

Earnings Call

DGX Earnings Call Summary for Q1/2026Upcoming8:30 AM on Apr 21, 2026

DGX Earnings Call Summary for Q4/20258:30 AM on Feb 10, 2026

DGX Earnings Call Summary for Q3/20258:30 AM on Oct 21, 2025

DGX Earnings Call Summary for Q2/20258:30 AM on Jul 22, 2025

DGX Earnings Call Summary for Q1/20258:30 AM on Apr 22, 2025

You can ask Aime